» Articles » PMID: 15543619

Lymphoid Gene Expression As a Predictor of Risk of Secondary Brain Tumors

Overview
Date 2004 Nov 16
PMID 15543619
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Gene expression profiles are tissue-specific but may also reflect germ-line-driven expression patterns across tissue types. Previously, using a targeted pharmacologic approach, we identified germ-line polymorphisms in a single gene (thiopurine methyltransferase) associated with the risk of irradiation- and chemotherapy-induced secondary brain tumors in children with acute lymphoblastic leukemia (ALL). To identify additional candidate genetic risk factors, in identically treated patients, we compared the gene expression profiles of diagnostic ALL blasts of those who did develop irradiation-associated brain tumors (n = 9) with the profiles from those who did not (n = 33). Weighted rank regression was used to identify 33 probe sets associated with the time-dependent development of brain tumors; k-means clustering (k = 2) identified 2 groups that differed significantly in cumulative incidence of brain tumors (P = 0.012). Permutation analysis was used to estimate the probability (P = 0.18) of obtaining 2 such clusters by chance. Linear discriminant analysis (time-independent categorization of outcome) was used to identify 70 probe sets whose expression differentiated between the 2 groups of patients. Permutation analyses (n = 1,000) was used to estimate the probability of selecting these probe sets by chance (P = 0.055). Five probe sets were in common between the time-independent and time-dependent methods. The distinguishing genes are involved in neural growth (FGFR1) and in nuclear trafficking (HNRPL, KPNB1). These data suggest that gene expression profiling from accessible tissues may identify targets involved in therapy-related malignancies in unrelated tissues.

Citing Articles

KDELR3 overexpression as a novel prognostic and diagnostic biomarker in glioma: comprehensive bioinformatic analysis insights.

Feng J, Zhao L, Fu L, Wang X, Ma D, Shang M Sci Rep. 2024; 14(1):30783.

PMID: 39730475 PMC: 11681132. DOI: 10.1038/s41598-024-80991-1.


Targeting nuclear import and export in hematological malignancies.

Nachmias B, Schimmer A Leukemia. 2020; 34(11):2875-2886.

PMID: 32624581 PMC: 7584478. DOI: 10.1038/s41375-020-0958-y.


The role of KPNβ in neuro-oncology.

Lilley M, Farassati F Onco Targets Ther. 2017; 10:2067-2068.

PMID: 28435297 PMC: 5391822. DOI: 10.2147/OTT.S136247.


Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds.

Guntuku L, Naidu V, Yerra V Curr Neuropharmacol. 2016; 14(6):567-83.

PMID: 26791479 PMC: 4981742. DOI: 10.2174/1570159x14666160121115641.


Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma.

Yang L, Hu B, Zhang Y, Qiang S, Cai J, Huang W Med Oncol. 2015; 32(4):128.

PMID: 25794490 DOI: 10.1007/s12032-015-0559-1.